Datafin

Data-driven stock analysis platform for global investors.

Sitemap
HomeScreenerValuationSector Analysis
Resources
LibraryDatafin GuideMetric MethodologyValuation MethodologiesFAQPricingWho Is Datafin?Communication
Legal
Privacy PolicyTerms of UseCookie PolicyKVKK NoticeRefund Policy
Data Sources

Financial data sourced from official regulatory filings and verified market data providers. Metrics calculated using GAAP/IFRS standards.

Disclaimer

The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

Investment decisions involve risk. Verify data independently and consult a licensed advisor when needed.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved.

Last updated: April 2026

TLX PEER ANALYSIS

TELIX Pharmaceuticals Ltd — metric-by-metric comparison with peers and the industry median

TLXTELIX Pharmaceuticals Ltd

🇦🇺 Australia · AU · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityGrowthFinancial Health
TLXIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
TLX-31.0%TARS+70.6%NRIX+99.1%TRVI+217.5%COGT+308.7%IRON+51.1%
Year-to-Date (YTD)
TLX+48.0%TARS-17.3%NRIX+28.1%TRVI+48.5%COGT+12.5%IRON+0.8%
1-Year
Split-adjusted
TLX-31.0%MSB+27.0%
Year-to-Date (YTD)
TLX+48.0%MSB-25.7%

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better
TLX-1.8%TARS-14.0%NRIX-61.4%TRVI-33.6%COGT-85.7%IRON-35.8%Median -47.5%

Net Margin

Higher is better
TLX-0.9%TARS-9.0%NRIX-411.4%TRVI—COGT—IRON2,016.9%Median -125.7%

Revenue Growth

Higher is better
TLX56.3%TARS129.0%NRIX27.2%TRVI-100.0%COGT-100.0%IRON—Median 5.1%

P/E

Lower is better

ROE

Higher is better
TLX-1.8%MSB-11.3%Median -47.5%

Net Margin

Higher is better
TLX-0.9%MSB-115.3%Median -125.7%

Revenue Growth

Higher is better
TLX56.3%MSB410.4%Median 5.1%

All Metrics

Valuation
MetricTLXTARSNRIXTRVICOGTIRONInd. Median
P/E——————18.00
P/B6.268.345.5615.724.43●4.483.60
EV/EBITDA118.24—————15.20
P/S3.185.4437.28——-257.25●10.43
Financial Health
MetricTLXTARSNRIXTRVICOGTIRONInd. Median
Current Ratio1.433.746.0124.75●15.1424.005.90
Debt/Equity112.3%25.4%12.2%0.4%●39.3%4.5%10.9%
NetDebt/EBITDA13.137.471.76●3.761.792.931.15
Profitability
MetricTLXTARSNRIXTRVICOGTIRONInd. Median
Net Margin-0.9%-9.0%-411.4%——2,016.9%●-125.7%
ROE-1.8%●-14.0%-61.4%-33.6%-85.7%-35.8%-47.5%
ROA-0.7%●-8.9%-47.2%-31.8%-59.7%-33.1%-35.8%
EBITDA Margin3.0%-7.5%-382.1%——1,988.9%●-105.8%
Growth + Dividend
MetricTLXTARSNRIXTRVICOGTIRONInd. Median
Rev. Growth56.3%129.0%●27.2%-100.0%-100.0%—5.1%
NI Growth——————12.1%
Div. Yield——————0.2%
Payout——————0.0%
Valuation
MetricTLXMSBInd. Median
P/E——18.00
P/B6.26—3.60
EV/EBITDA118.24—15.20
P/S3.18●30.9910.43
Financial Health
MetricTLXMSBInd. Median
Current Ratio1.43—5.90
Debt/Equity112.3%—10.9%
NetDebt/EBITDA13.13—1.15
Profitability
MetricTLXMSBInd. Median
Net Margin-0.9%●-115.3%-125.7%
ROE-1.8%●-11.3%-47.5%
ROA-0.7%●-8.6%-35.8%
EBITDA Margin3.0%●-76.6%-105.8%
Growth + Dividend
MetricTLXMSBInd. Median
Rev. Growth56.3%410.4%●5.1%
NI Growth——12.1%
Div. Yield—0.0%0.2%
Payout—0.0%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on TLX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 8, 26. This content is for informational purposes only and is not investment advice.